Thanks for posting, theresnobeachhere:
"As we continue to focus on regenerative ophthalmology, this scientific validation of one of our leading non-ophthalmic programs enables us to seek collaborations with external groups that have the resources necessary to bring the results of our ground-breaking technologies to patients in need."
Still a buyer. They will partner before larger Phase 2. Terms are the only uncertainty, but these guys know what they have and won't give it away for free.
Half of macular degeneration patients saw improvement in vision
RPE cells from ESC's help in macular degeneration
Why are there more and more headlines like these:
Avera Cancer Institute Approved to Offer Comprehensive Provenge Cancer Treatment.
Harbin Clinic, Georgia's largest physician-owned multi-specialty clinic approved to Offer Provenge, a Cutting Edge Treatment for Prostate Cancer.
Who should we trust? Clinics investing time and money for a cure, or anonymous message board posters who say the end is near? Hmmmmmmmm...........
Yes, Dendreon is a buy. And, yes, the tax loss carry-forwards are important and will be allowed despite the screams of bashers . The aquiring company is simply not allowed to turn around and sell their aquisition in less than 2 years after takijng advantage of the carry-forwards.
As to Peso's claim concerning the aquiring company being headquartered in Ireland, someone should ask who he has in mind and why.
First quarter improvement in earnings was the watershed moment. Second quarter will be confirmation. Add Europe and partner--Kaboom!
Shorts are covering for a reason. Wall Street always likes to make the ball bounce--they don't make money from stasis.
It's a buy IMHO.
Yes, that was a GREAT closing paragraph. We can hope that it gets some attention from the right folks, but we can also write a few letters to help. I've already sent a couple. Join me in writing some more. The people who say, "it does nothing," are making excuses. Enough committed people can get anything done.